Dbs ms 500
The DBS-MS 500 is a laboratory equipment designed for the analysis of dried blood spot (DBS) samples. It provides an automated solution for the extraction and analysis of analytes from DBS samples using mass spectrometry (MS) technology. The core function of the DBS-MS 500 is to facilitate the processing and analysis of DBS samples, enabling researchers and laboratories to efficiently and accurately measure the presence and concentration of various compounds in dried blood.
Lab products found in correlation
4 protocols using dbs ms 500
Quantitative Analysis of Compounds by HPLC-MS/MS
Multivitamin Analysis in Dried Blood
DBS-MS for Tramadol and Metabolite Analysis
photographed with a built-in camera before and after the extraction process, to document the samples, check for the presence of a blood spot, to center the extraction head position, and to verify where the extraction took place. Methanolic internal standard solution (20 μL spray volume, containing 25 ng/mL cis-tramadol-13 C, D3, and 10 ng/mL O-Desmethyl-cis-tramadol-D6) was sprayed in a homogenous layer of 1 cm 2 over the center of each spot (flow rate of 120 μL/min). Afterward, the internal standard solution was dried for 60 s at room temperature. In contrast to mixing the internal standard into the extraction solvent, this procedure enables compensating for extraction differences (recovery bias) 8, (link)9 (link) . The extraction of a 4.
Validation of Newborn Screening DBS Assays
& Chemicals GmBH, Gräfelfing, Germany); and
(2) NeoBase Non-derivatized MSMS kit (with succinylacetone assay; PerkinElmer, Waltham [MA], US) were validated for use in the study. In addition to a manual puncher and an autopuncher for DBS preparation, a fully automated online extraction system (DBS-MS 500; CAMAG, Muttenz, Switzerland) was also evaluated. The precision and local reference intervals of the commercial assay kits are listed in Table 1. Our laboratory has participated in the Newborn Screening Quality Assurance Programme organised by the US Centers for Disease Control and Prevention (CDC) since 2011. The disease panel included in the study is shown in Table 2. 8, 10, 11 Step 6: Reporting Chemical pathologists were responsible for reporting of positive results to the paediatricians. The CDC cut-off for clinical decision (https://wwwn.cdc.gov/ NSQAP/Restricted/CDCCutOffs.aspx) and the Region 4 Stork Collaborative Project (https://www. clir-r4s.org/) data interpretation tools were applied during interpretation of the results.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!